PTC Therapeutics

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The firm's portfolio includes Translarna, Emflaza, Tegsedi, Waylivra, and Evrysdi. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

PTC Therapeutics reports robust earnings, faces data release delays

PTC Therapeutics demonstrated strong financial performance and revenue growth in Q4 2022, setting a positive trajectory for 2023.
While facing challenges such as data release delays and regulatory engagements, the company's innovative pipeline and commercial successes position it well for future opportunities.
With upcoming data readouts, regulatory discussions, and market expansion initiatives, PTC is poised to navigate challenges and leverage opportunities for continued growth and impact.

PTC Therapeutics achieves record revenue, faces regulatory challenges and growth opportunities

PTC Therapeutics reported strong financial performance in Q1 2023, with a clear path towards achieving revenue targets. While facing challenges such as regulatory interactions and data expectations, the company is leveraging opportunities in upcoming study results and strategic initiatives to drive growth and market differentiation.

PTC Therapeutics reports strong Q2 revenue and advances pipeline

PTC Therapeutics showcased robust financial performance, positive trial outcomes, and strategic cost-saving measures in Q2 2023.
The company's strong revenue growth, global expansion plans, and pipeline advancements position it for sustained success.
Challenges include addressing analyst inquiries, navigating regulatory pathways, and ensuring market access post-2024.
Opportunities in product launches, regulatory activities, and strategic partnerships offer avenues for continued growth and innovation.

PTC Therapeutics reports robust Q3 earnings and strategic growth plans

PTC Therapeutics demonstrated strong financial performance and strategic partnerships in Q3 2023 earnings call.
The company's focus on pipeline advancement, commercial growth, and regulatory strategies positions it for future success.
While facing challenges in regulatory compliance and product comparability, PTC Therapeutics is leveraging opportunities for revenue growth and market expansion.

PTC Therapeutics posts robust Q4 earnings amidst regulatory challenges

PTC Therapeutics delivered strong financial performance in Q4 2023, driven by revenue growth and transformative gene therapy results, despite challenges from the CHMP opinion.
The company's strengths lie in its solid balance sheet, positive community feedback, and FDA alignment on registration programs, positioning it for future growth and approvals.
Opportunities abound in the launch of sepiapterin, accelerated approval discussions with the FDA, and promising programs for FA and ALS, signaling a positive outlook for PTC.

PTC Therapeutics reports robust Q1 performance amidst regulatory milestones

PTC Therapeutics demonstrated strong financial and operational performance in Q1 2024, driven by revenue growth and regulatory progress.
While facing challenges such as delays in European market access and regulatory complexities, the company remains focused on key therapeutic advancements.
Opportunities lie in upcoming clinical results, potential market expansions, and strategic regulatory pathways for accelerated product approvals.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.

NEW YORK, NY / ACCESSWIRE / March 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC") (NASDAQ:PTCT) concerning possible violations of federal securities laws. On September 15, 2023, PTC announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a negative opinion of its drug Translarna, for the treatment of nonsense mutation Duchenne muscular dystrophy.

PTC Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by PTC (PTCT)

NEW YORK, NY / ACCESSWIRE / March 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC") (NASDAQ:PTCT) concerning possible violations of federal securities laws. On September 15, 2023, PTC announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a negative opinion of its drug Translarna, for the treatment of nonsense mutation Duchenne muscular dystrophy.

PTC Therapeutics, Inc. (PTCT) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky, LLP Investigates

NEW YORK, NY / ACCESSWIRE / March 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC") (NASDAQ:PTCT) concerning possible violations of federal securities laws. On September 15, 2023, PTC announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a negative opinion of its drug Translarna, for the treatment of nonsense mutation Duchenne muscular dystrophy.

PTCT ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of PTC Therapeutics, Inc. Shareholders Who Lost Money

NEW YORK, NY / ACCESSWIRE / March 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC") (NASDAQ:PTCT) concerning possible violations of federal securities laws. On September 15, 2023, PTC announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a negative opinion of its drug Translarna, for the treatment of nonsense mutation Duchenne muscular dystrophy.

ATTENTION PTC Therapeutics, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights

NEW YORK, NY / ACCESSWIRE / March 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC") (NASDAQ:PTCT) concerning possible violations of federal securities laws. On September 15, 2023, PTC announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a negative opinion of its drug Translarna, for the treatment of nonsense mutation Duchenne muscular dystrophy.

ATTENTION PTC Therapeutics, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights

NEW YORK, NY / ACCESSWIRE / March 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC") (NASDAQ:PTCT) concerning possible violations of federal securities laws. On September 15, 2023, PTC announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a negative opinion of its drug Translarna, for the treatment of nonsense mutation Duchenne muscular dystrophy.

PTC Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - PTCT

NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC") (NASDAQ:PTCT) concerning possible violations of federal securities laws. On September 15, 2023, PTC announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a negative opinion of its drug Translarna, for the treatment of nonsense mutation Duchenne muscular dystrophy.

Lost Money on PTC Therapeutics, Inc.(PTCT)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

PTC Therapeutics, Inc. (PTCT) Q4 2023 Earnings Call Transcript

While the top- and bottom-line numbers for PTC Therapeutics (PTCT) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Here's What Key Metrics Tell Us About PTC Therapeutics (PTCT) Q4 Earnings

PTC Therapeutics (PTCT) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of $0.29. This compares to loss of $2.35 per share a year ago.

PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates

– 34% year-over-year growth in 2023 total revenue – – Global filings of sepiapterin remain on track with first submission of the EU MAA expected in March –   – Potential NDA submission for vatiquinone for Friedreich ataxia expected in  late 2024 – SOUTH PLAINFIELD, N.J. , Feb. 29, 2024 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2023.

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

NEW YORK, NY / ACCESSWIRE / February 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC") (NASDAQ:PTCT) concerning possible violations of federal securities laws. On September 15, 2023, PTC announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a negative opinion of its drug Translarna, for the treatment of nonsense mutation Duchenne muscular dystrophy.

PTC Therapeutics, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - PTCT

Besides Wall Street's top -and-bottom-line estimates for PTC Therapeutics (PTCT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

Wall Street's Insights Into Key Metrics Ahead of PTC Therapeutics (PTCT) Q4 Earnings

SOUTH PLAINFIELD, N.J. , Feb. 15, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full year 2023 financial results and provide an update on the company's business and outlook on Thursday, Feb. 29, at 4:30 p.m.

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PTC Therapeutics (PTCT) to Report Q4 Results: Wall Street Expects Earnings Growth

PTC stock dipped Friday after European regulators voted to withdraw the biotech company's treatment for a severe form of muscular dystrophy.

PTC Therapeutics Recovers, Mostly, After European Officials Reject DMD Drug

The European health regulator's advisory panel issued a negative opinion for PTC Therapeutics' drug to treat Duchenne muscular dystrophy (DMD), an inherited progressive muscle-wasting disorder, the company said on Thursday.

PTC Therapeutics' muscle disorder drug fails to secure EU regulator backing

SOUTH PLAINFIELD, N.J. , Jan. 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion following the re-examination procedure for the conditional marketing authorization of Translarna™ (ataluren).

CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure

– Unaudited 2023 total revenue of $ 946 million, representing 35% year-over-year growth – – Regulatory filings in the EU and US for sepiapterin in PKU, a potential $1 billion global commercial opportunity, remain on track for 2024 – – Multiple study readouts planned for 2024, including 12-month interim data from the PIVOT-HD study of PTC518 in HD patients – SOUTH PLAINFIELD, N.J. , Jan. 8, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its commercial progress and R&D pipeline at the 42nd Annual J.P.

PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference

SOUTH PLAINFIELD, N.J. , Jan. 3, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the 42nd Annual J.P.

PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare Conference

SOUTH PLAINFIELD, N.J. , Dec. 5, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today an update on Translarna™ (ataluren) regulatory activities in Europe and the United States.

PTC Therapeutics Provides Updates on Translarna™ Regulatory Activities

PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q3 2023 Earnings Conference Call February 8, 2023 9:00 AM ET Company Participants Jane Hanlon - Associate Director, Investor Relations Matthew Klein - Chief Executive Officer Eric Pauwels - Chief Business Officer Kylie O'Keefe - Chief Commercial Officer Pierre Gravier - Chief Financial Officer Conference Call Participants Eric Joseph - J.P. Morgan Kristen Kluska - Cantor Fitzgerald Samantha Corwin - William Blair David Lebowitz - Citi Brian Abrahams - RBC Capital Markets Colin Bristow - UBS Jeff Hung - Morgan Stanley Alexander Xenakis - Truist Securities Joseph Schwartz - Leerink Partners Gena Wang - Barclays Paul Choi - Goldman Sachs Tazeen Ahmad - Bank of America Operator Thank you for standing by and welcome to the PTC Therapeutics Third Quarter 2023 Financial Results Conference Call.

PTC Therapeutics, Inc. (PTCT) Q3 2023 Earnings Call Transcript

PTC Therapeutics (NASDAQ: PTCT ) stock is falling on Friday after the biopharmaceutical company released its earnings report for the third quarter of 2023. The bad news for PTCT stock starts with its earnings per share of -$1.76.

Why Is PTC Therapeutics (PTCT) Stock Down 23% Today?

PTC Therapeutics (PTCT) came out with a quarterly loss of $1.76 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $1.53 per share a year ago.

PTC Therapeutics (PTCT) Reports Q3 Loss, Lags Revenue Estimates

– Third quarter 2023 total revenues of $197 million and remain on target for 2023 revenue guidance – – PTC strengthened its financial position following recent restructuring initiatives and Royalty Pharma transaction – – PTC provides regulatory updates for pipeline programs – SOUTH PLAINFIELD, N.J. , Oct. 26, 2023 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ending September 30, 2023.

News for PTC Therapeutics Stock (PTCT)